2018-08-09 11:12:24

Is therapeutic diagnostics the key to completely curing colorectal cancer?

Historically, radioimmunotherapy is not suitable for the treatment of solid tumors, but new research published in the Journal of Nuclear Medicine suggests that such studies may be altered.

In preclinical trials, new treatments for colorectal cancer achieve a 100% cure rate without toxic side effects.

The Memorial Sloan Kettering Cancer Center and the research team at Massachusetts Institute of Technology tested the mouse model's three-step method. They are focused on over 95% of the antigens found in human primary and metastatic colorectal cancer called glycoprotein A33.

They are GPA33 (1-177 and S-2- (4-aminobenzyl) 1, 4, 7, 10), a bispecific antibody against the A33 tumor antigen which is a secondary antibody for small molecule radioactive hapten A complex of tetraazacyclododecanetetraacetic acid (177 Lu - DOTA - Bn) targeted to the target.

Nine mice were randomly selected for DOTA pretargeting radioimmunotherapy (PRIT) treatment. SPECT / CT imaging is used to monitor the therapeutic response and to measure the amount of radiation absorbed by the tumor.

All mice were well tolerated, and no microscopic examination showed signs of residual cancer. Radiation damage to major organs such as bone marrow and kidney is not detected.

Based on these preliminary findings, we believe that anti-GPA33-DOTA-PRIT method is an effective treatment for GPA33 positive colorectal cancer in humans and other cancers.

This method aims to use many fine antibodies targeted to human tumor antigens and is suitable for almost all solid and liquid tumors present in the human body. This may be necessary to treat advanced diseases such as colon cancer, breast cancer, pancreatic cancer, melanoma, lung cancer and esophageal cancer.

Theranostics is the main theme of the discussion at this year's SNMMI Annual Meeting. A group of Canadian researchers presented their work at a seminar on the use of therapeutic diagnostic agents for the treatment of personalized neuroendocrine cancer.

"When we are being treated with nuclear medicine, unlike other medications, including chemotherapy and drugs, we see exactly where our treatment is in our organs and tumors, by doing some scanning after medication Dr. Beauregard Dr. Jean-Mathieu of Laval University of Quebec told HCB News at the meeting.